Moleculin Biotech(MBRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MBRX Moleculin Biotech

Closed 12-18 16:00:00 EST

3.83

-0.31

-7.49%

盘后3.80

-0.03-0.78%

19:58 EST

High4.16	Low3.81	Vol222.18K
Open4.07	D1 Closing4.14	Amplitude8.49%
Mkt Cap7.91M	Tradable Cap7.62M	Total Shares2.06M
T/O887.53K	T/O Rate11.16%	Tradable Shares1.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MBRX","market":"US","secType":"STK","nameCN":"Moleculin Biotech","latestPrice":3.83,"timestamp":1766091600000,"preClose":4.14,"halted":0,"volume":222178,"hourTrading":{"tag":"盘后","latestPrice":3.8,"preClose":3.83,"latestTime":"19:58 EST","volume":16811,"amount":63911.0119,"timestamp":1766105887763},"delay":0,"floatShares":1990300,"shares":2064000,"eps":-78.860825,"marketStatus":"Closed","change":-0.31,"latestTime":"12-18 16:00:00 EST","open":4.07,"high":4.1616,"low":3.81,"amount":887530.901752,"amplitude":0.084928,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-78.860825,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.14,"preHourTrading":{"tag":"盘前","latestPrice":4.01,"preClose":4.14,"latestTime":"09:29 EST","volume":13685,"amount":55042.71904249999,"timestamp":1766068184795},"postHourTrading":{"tag":"盘后","latestPrice":3.8,"preClose":3.83,"latestTime":"19:58 EST","volume":16811,"amount":63911.0119,"timestamp":1766105887763},"volumeRatio":0.164871},"requestUrl":"/m/hq/s/MBRX/tweets","defaultTab":"tweets","newsList":[{"id":"2592918178","title":"Moleculin Reports Positive Phase 1 Results for WP1066 in Pediatric Brain Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918178","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918178?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:31","pubTimestamp":1765978266,"startTime":"0","endTime":"0","summary":"Moleculin Biotech Inc. has announced positive results from a Phase 1 clinical trial evaluating WP1066 for the treatment of pediatric recurrent malignant brain tumors. The trial, conducted at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta and led by Dr. Tobey MacDonald, demonstrated that WP1066 induces anti-tumor immune responses. The results, which found WP1066 to be safe and effective, were recently published in the Journal of Clinical Investigation Insight and support the advancement to a Phase 2 trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL2L4hf3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2592918925","title":"Moleculin Biotech Inc - WP1066 Found Safe and Effective, Warranting Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918925","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918925?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:31","pubTimestamp":1765978260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6QLSKT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2592918904","title":"Moleculin Announces Positive Results From Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918904?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:31","pubTimestamp":1765978260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6QLSKT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MBRX"],"gpt_icon":0},{"id":"2590151885","title":"Moleculin Biotech Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2590151885","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590151885?lang=en_us&edition=fundamental","pubTime":"2025-12-11 19:44","pubTimestamp":1765453440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MBRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 06:44 ET (11:44 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX"],"gpt_icon":0},{"id":"2590059587","title":"Moleculin Biotech Raises $6.8 Million Through Warrant Exercises","url":"https://stock-news.laohu8.com/highlight/detail?id=2590059587","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590059587?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:30","pubTimestamp":1765373420,"startTime":"0","endTime":"0","summary":"Moleculin Biotech Inc. has announced agreements with certain holders for the immediate exercise of outstanding warrants, resulting in gross proceeds of approximately $6.5 million before fees. The exercised warrants cover 727,969 shares originally issued in February 2025 at $6.63 per share and 316,360 shares issued in August 2025 at $6.3219 per share. In connection with this transaction, Moleculin will issue new unregistered warrants to purchase up to 2,610,823 shares of common stock at an exercise price of $6.63 per share, exercisable upon shareholder approval for five years. The company intends to use the proceeds for working capital and general corporate purposes. Roth Capital Partners and Maxim Group LLC served as financial advisors for the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL1ngN56:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","BK4585","IE00BKPKM429.USD","SG9999014013.SGD","MBRX","SG9999014005.SGD","BK4112","LU2210149790.SGD","SG9999014039.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","NDAQ","SG9999014021.USD","LU2095319765.USD","BK4139"],"gpt_icon":0},{"id":"2590496523","title":"Moleculin Biotech Nears First Unblinding in Pivotal Phase 3 AML Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590496523","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590496523?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:07","pubTimestamp":1765285638,"startTime":"0","endTime":"0","summary":"Moleculin Biotech Inc. has announced the completion of treatment for the first 45 patients in its pivotal Phase 2B/3 \"MIRACLE\" clinical trial, evaluating Annamycin in combination with cytarabine for adult patients with relapsed or refractory acute myeloid leukemia . As of early December 2025, 78% of the target subjects for the first interim unblinding have consented across seven countries, and recruitment continues. The company expects to complete treatment of the first cohort and conduct the first planned unblinding of data in the first quarter of 2026. Results from this interim analysis have not yet been presented. The trial will continue enrolling the remaining subjects to reach a total of 90 for Part A, with a second unblinding planned to inform dose selection for Part B.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL46x5BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX","SG9999014021.USD","BK4588","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","SG9999014005.SGD","BK4139","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4585","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2590349523","title":"Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “Miracle” Phase 3 Aml Trial on Pace for Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349523","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349523?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:07","pubTimestamp":1765285620,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA7XF4LK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MBRX"],"gpt_icon":0},{"id":"2589353040","title":"Moleculin Biotech Partners with CIC biomaGUNE to Study Annamycin for Brain Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353040","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353040?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:21","pubTimestamp":1765200072,"startTime":"0","endTime":"0","summary":"Moleculin Biotech Inc. has announced a new collaboration with CIC biomaGUNE, a non-profit research organization in Spain, to conduct preclinical studies on Annamycin for the treatment of glioblastoma multiforme, a form of brain cancer. Under the agreement, Moleculin will provide Annamycin while CIC biomaGUNE, led by Principal Investigator Jesús Ruiz-Cabello, will evaluate the effects of intra-arterial delivery of both liposomal and free Annamycin compared to other treatments in mouse models. This partnership aims to explore new therapeutic options for hard-to-treat brain tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL5Pb3px:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MBRX"],"gpt_icon":0},{"id":"2589530493","title":"Moleculin Announces New Annamycin Collaboration in Brain Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2589530493","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589530493?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:21","pubTimestamp":1765200060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA3LBV0D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MBRX"],"gpt_icon":0},{"id":"2589353045","title":"Moleculin Biotech Inc - Enters Research Agreement With Cic Biomagune","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353045?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:21","pubTimestamp":1765200060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA3LBV0D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MBRX"],"gpt_icon":0},{"id":"2587730466","title":"Moleculin Biotech trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2587730466","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587730466?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:50","pubTimestamp":1764366614,"startTime":"0","endTime":"0","summary":"16:50 EST Moleculin Biotech (MBRX) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaki...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moleculin-biotech-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moleculin-biotech-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2587731077","title":"Moleculin Biotech Enacts 1-for-25 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2587731077","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587731077?lang=en_us&edition=fundamental","pubTime":"2025-11-29 02:17","pubTimestamp":1764353832,"startTime":"0","endTime":"0","summary":"Moleculin Biotech Inc. has announced a 1-for-25 reverse stock split of its common stock, effective December 1, 2025. Following the split, the number of outstanding shares will be reduced from approximately 51.7 million to about 2.1 million, while the number of authorized shares remains unchanged. The company's common stock will continue to trade on Nasdaq under the ticker symbol \"MBRX\" with a new CUSIP number.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 28, 2025, and is solely responsible for the informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL5bB4vY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2586628132","title":"BUZZ-U.S. STOCKS ON THE MOVE-Nucor, Natgas companies, health insurers","url":"https://stock-news.laohu8.com/highlight/detail?id=2586628132","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586628132?lang=en_us&edition=fundamental","pubTime":"2025-11-27 02:48","pubTimestamp":1764182892,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Nucor, Natgas companies, health insurersEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nL6N3X20M9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FCX","VG","PD","HPQ","OVV","LU1852331112.SGD","SSP","NTNX","SCCO","SG9999014013.SGD","HUM","IE00B3S45H60.SGD","SG9999004303.SGD","IRWD","AMBA","ZS","HLF","SM","GRND","MBRX","URBN","HL","TSYW.SI","CLFD","AMTM","SGXZ31699556.SGD","PB","DE","NUE","LU1064131342.USD","LU0187121727.USD","PSBD","XOM","SPRC","IE00B19Z3B42.SGD","ATMU","CTRA","WOOF","CDE","WDAY","ADSK"],"gpt_icon":1},{"id":"2586126504","title":"BUZZ-U.S. STOCKS ON THE MOVE-Robinhood Markets, Oracle, Grindr","url":"https://stock-news.laohu8.com/highlight/detail?id=2586126504","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586126504?lang=en_us&edition=fundamental","pubTime":"2025-11-26 23:41","pubTimestamp":1764171707,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Robinhood Markets, Oracle, GrindrEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nL6N3X20VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BK4W5M84.HKD","LU1074936037.SGD","GRND","LU0203345920.USD","PD","ATMU","SG9999014559.SGD","BK4592","LU1989772840.SGD","SSP","HL","CLFD","SM","WDAY","VG","LU1366192091.USD","LU1582986359.USD","PSBD","TSYW.SI","LU0175139822.USD","IE00B19Z3B42.SGD","CDE","LU0788109121.HKD","WOOF","ORCL","IE00B19Z9505.USD","DE","OVV","LU0861579265.USD","SPRC","URBN","IRWD","FCX","LU0345780521.USD","NTNX","CTRA","XOM","AMBA","HPQ","ZS","HOOD","MBRX","ADSK","AMTM","SCCO"],"gpt_icon":1},{"id":"2586265836","title":"BUZZ-Moleculin Biotech falls after reverse stock split move","url":"https://stock-news.laohu8.com/highlight/detail?id=2586265836","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586265836?lang=en_us&edition=fundamental","pubTime":"2025-11-26 23:04","pubTimestamp":1764169442,"startTime":"0","endTime":"0","summary":"BUZZ-Moleculin Biotech falls after reverse stock split move** Shares of drug developer Moleculin Biotech MBRX.O falls 22% at $0.28 in early trading** Co says it will implement 1-for-25 reverse stock split effective December 1** A 1-for-25 split means every 25 existing shares will be combined into 1 new share** Split reduces outstanding shares to about 2.1 million from 51.7 million; authorized shares unchanged at 500 mln - MBRX** Co's shares will continue to trade on the Nasdaq under the ticker \"MBRX,\" but with a new identification number - MBRX** Co says shareholders who end up with fractional shares after the split will receive cash instead** Including session's move, stock down ~83% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nL4N3X213H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2586250286","title":"Moleculin Biotech Inc - to Effect 1-for-25 Reverse Stock Split December 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586250286?lang=en_us&edition=fundamental","pubTime":"2025-11-26 22:00","pubTimestamp":1764165600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUA5CR8Z1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MBRX"],"gpt_icon":0},{"id":"2585297671","title":"Moleculin Biotech Appeals Nasdaq Delisting Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2585297671","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585297671?lang=en_us&edition=fundamental","pubTime":"2025-11-22 06:01","pubTimestamp":1763762472,"startTime":"0","endTime":"0","summary":"Moleculin Biotech ( ($MBRX) ) has shared an update. On November 20, 2025, Moleculin Biotech received a delist determination letter from Nasdaq, ind...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moleculin-biotech-appeals-nasdaq-delisting-decision?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moleculin-biotech-appeals-nasdaq-delisting-decision?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":[".IXIC","SQQQ","MBRX","TSYW.SI","QID","USJW.SI","PSQ","USAW.SI","BK4139","NQmain","NVIW.SI","TQQQ","MNQmain","QLD"],"gpt_icon":0},{"id":"2585126956","title":"Moleculin Biotech Faces Nasdaq Delisting After Equity Rule Violation","url":"https://stock-news.laohu8.com/highlight/detail?id=2585126956","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585126956?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:34","pubTimestamp":1763760859,"startTime":"0","endTime":"0","summary":"Moleculin Biotech Inc. has announced that it received a delisting determination letter from the Nasdaq Stock Market after failing to regain compliance with the minimum $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550. The company did not meet alternative listing standards related to market value or net income. Moleculin intends to appeal the decision to a hearing panel, which will allow its shares to continue trading on the Nasdaq Capital Market under the symbol \"MBRX\" while the appeal is pending. If the appeal is unsuccessful, the company's securities are at risk of being delisted as early as December 2, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original conte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL6xcmSz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2583523143","title":"Moleculin Biotech Reports Increased Loss Amid Ongoing Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2583523143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583523143?lang=en_us&edition=fundamental","pubTime":"2025-11-14 12:18","pubTimestamp":1763093912,"startTime":"0","endTime":"0","summary":"Moleculin Biotech ( ($MBRX) ) has released its Q3 earnings. Here is a breakdown of the information Moleculin Biotech presented to its investors. Mo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moleculin-biotech-reports-increased-loss-amid-ongoing-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moleculin-biotech-reports-increased-loss-amid-ongoing-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MBRX"],"gpt_icon":0},{"id":"2583668593","title":"Moleculin Biotech Nears First Unblinding Milestone in Pivotal Phase 3 AML Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2583668593","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583668593?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:36","pubTimestamp":1763041011,"startTime":"0","endTime":"0","summary":"Moleculin Biotech Inc. has announced an update on the enrollment progress of its pivotal Phase 2B/3 \"MIRACLE\" clinical trial evaluating Annamycin in combination with cytarabine for adult patients with relapsed or refractory acute myeloid leukemia . As of November 4, 2025, 60% of the targeted 45 subjects for the first planned interim unblinding have consented to participate. The company anticipates completing treatment of these initial 45 patients in the first quarter of 2026, with initial unblinded data expected to be released thereafter. Additional subjects continue to be identified, and the second unblinding is anticipated in the first half of 2026. The trial is being conducted across sites in five countries. Results from this study have not yet been presented.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL9YZcLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.moleculin.com","stockEarnings":[{"period":"1week","weight":-0.1429},{"period":"1month","weight":-0.6096},{"period":"3month","weight":-0.5981},{"period":"6month","weight":-0.3798},{"period":"1year","weight":-0.911},{"period":"ytd","weight":-0.9026}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.050477},{"month":2,"riseRate":0.222222,"avgChangeRate":-0.078146},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.125735},{"month":4,"riseRate":0.444444,"avgChangeRate":0.079306},{"month":5,"riseRate":0.111111,"avgChangeRate":-0.074587},{"month":6,"riseRate":0.222222,"avgChangeRate":0.038146},{"month":7,"riseRate":0.6,"avgChangeRate":0.174639},{"month":8,"riseRate":0.2,"avgChangeRate":-0.127636},{"month":9,"riseRate":0.2,"avgChangeRate":-0.037317},{"month":10,"riseRate":0.1,"avgChangeRate":-0.140808},{"month":11,"riseRate":0.5,"avgChangeRate":0.009369},{"month":12,"riseRate":0.3,"avgChangeRate":-0.097759}],"exchange":"NASDAQ","name":"Moleculin Biotech","nameEN":"Moleculin Biotech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Moleculin Biotech(MBRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Moleculin Biotech(MBRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Moleculin Biotech,MBRX,Moleculin Biotech股票,Moleculin Biotech股票老虎,Moleculin Biotech股票老虎国际,Moleculin Biotech行情,Moleculin Biotech股票行情,Moleculin Biotech股价,Moleculin Biotech股市,Moleculin Biotech股票价格,Moleculin Biotech股票交易,Moleculin Biotech股票购买,Moleculin Biotech股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Moleculin Biotech(MBRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Moleculin Biotech(MBRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction